Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
50 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Birch Pollen Allergy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Birch Pollen Allergy - Pipeline Review, H2 2014', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Birch Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Birch Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Birch Pollen Allergy Overview 6 Therapeutics Development 7 Pipeline Products for Birch Pollen Allergy - Overview 7 Pipeline Products for Birch Pollen Allergy - Comparative Analysis 8 Birch Pollen Allergy - Therapeutics under Development by Companies 9 Birch Pollen Allergy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Birch Pollen Allergy - Products under Development by Companies 13 Birch Pollen Allergy - Companies Involved in Therapeutics Development 14 ALK-Abello A/S 14 Allergopharma Joachim Ganzer KG 15 Anergis SA 16 Biomay AG 17 Circassia Pharmaceuticals plc 18 HAL Allergy BV 19 Stallergenes S.A. 20 Birch Pollen Allergy - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 ALK Birch Pollen Vaccine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 AllerT - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Birch-SPIRE - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BM-31 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Drug for Birch Pollen Allergy - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PL-102 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 rBet v1 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 rBet v1-FV - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Birch Pollen Allergy - Recent Pipeline Updates 38 Birch Pollen Allergy - Dormant Projects 40 Birch Pollen Allergy - Discontinued Products 41 Birch Pollen Allergy - Product Development Milestones 42 Featured News & Press Releases 42 Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 42 Feb 27, 2014: Phase IIb Results of Anergis� Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 42 Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT 42 Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT 43 Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT 44 Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment 44 Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen 45 Aug 31, 2010: Anergis's Ultra-Fast Treatment Against Birch Pollen Allergy Demonstrates Long Term Immunoregulatory Effect 45 Jul 17, 2009: Anergis Reports Encouraging Seasonal Clinical Results With Birch Pollen Allergy Drug Candidate AllerT 46 Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomay�s Bet v 1 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Birch Pollen Allergy, H2 2014 7 Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Late Stage Development, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2014 14 Birch Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 15 Birch Pollen Allergy - Pipeline by Anergis SA, H2 2014 16 Birch Pollen Allergy - Pipeline by Biomay AG, H2 2014 17 Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H2 2014 18 Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2014 19 Birch Pollen Allergy - Pipeline by Stallergenes S.A., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Route of Administration, H2 2014 24 Number of Products by Stage and Molecule Type, H2 2014 26 Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2014 38 Birch Pollen Allergy - Dormant Projects, H2 2014 40 Birch Pollen Allergy - Discontinued Products, H2 2014 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.